GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Total Current Liabilities

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Total Current Liabilities : $374.1 Mil (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Taro Pharmaceutical Industries's total current liabilities for the quarter that ended in Dec. 2023 was $374.1


Taro Pharmaceutical Industries Total Current Liabilities Historical Data

The historical data trend for Taro Pharmaceutical Industries's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Total Current Liabilities Chart

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 216.82 222.73 676.30 432.12 385.55

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 385.55 385.01 361.49 374.06

Taro Pharmaceutical Industries Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Taro Pharmaceutical Industries's Total Current Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=152.152+1.95
+Other Current Liabilities+Current Deferred Liabilities
=230.543+0.903
=385.5

Taro Pharmaceutical Industries's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=51.183+0
+Other Current Liabilities+Current Deferred Liabilities
=322.876+0
=374.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Taro Pharmaceutical Industries Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro to Announce Second Quarter Results on October 28, 2020

By Business Wire Business Wire 10-22-2020

Taro to Announce Third Quarter Results on January 27, 2022

By Business Wire Business Wire 01-21-2022

Taro Completes Acquisition of Alchemee

By Business Wire Business Wire 03-01-2022

Taro to Release Third Quarter Results on January 24, 2023

By Business Wire Business Wire 01-19-2023

Taro to Acquire Alchemee From Galderma

By Business Wire Business Wire 02-22-2022

Taro Announces Resignation of Chief Financial Officer

By Business Wire Business Wire 07-14-2021